Hormone receptor and Her2 neu (Her2) analysis
|
|
- Ethan Brown
- 6 years ago
- Views:
Transcription
1 ORIGINAL ARTICLE Impact of Triple Negative Phenotype on Breast Cancer Prognosis Henry G. Kaplan, MD* and Judith A. Malmgren, PhD à *Swedish Cancer Institute at Swedish Medical Center; HealthStat Consulting Inc.; and à Department of Epidemiology, School of Public Health and Community Medicine, University of Washington, Seattle, Washington n Abstract: Triple negative (TN) [estrogen receptor (ER), progesterone receptor (PgR)] (ER) PgR) Her2 neu)) breast cancer (BC) is an aggressive disease without tumor-specific treatment options. Our objective is to evaluate the relative contribution of combined Her2 neu (Her2) and hormone receptor (HR) status to BC progression. A prospective primary BC cohort of 1550 patients at our institution, stage I IV, from 1998 to 2003 were categorized by HR and Her2 status into ER+ PgR+ Her2) (HR+ Her2)) (n = 1134), ER+ PgR+ Her2+ [triple positive (TP)] (n = 138), ER) PgR) Her2) (TN) (n = 183), and ER) PgR) Her2+ (HR) Her2+) (n = 95). Clinical variables were chart abstracted and vital and disease status updated annually. Log-rank tests and Cox regression analyses were used to assess associations with survival. Patient age ranged from 21 to 88 years and average length of follow-up was 4.24 years. Overall survival at 5 years was 94% (HR+ Her2)), 91% (TP), and 81% (TN and HR) Her2+) (log rank test = 22.22, p < 0.001). Disease-specific survival at 5 years was 98% (HR+ Her2)), 93% (TP), 88% (TN), and 86% (HR) Her2+) (log rank test = 25.85, p < 0.001) and 5-year relapse-free survival was 95% (HR+ Her2)), 89% (TP), 84% (TN), and 76% (HR) Her2+) (log rank test = 20.29, p < 0.001). In a model adjusted for age, race, TNM stage, and treatment using HR+ Her2) patients as the reference group, recurrence risk was 1.98 for TP (95% CI = 1.02 to 3.84), 2.32 for TN (95% CI = 1.32 to 4.08), and 4.25 for HR) Her2+ patients (95% CI = 2.33, 7.75). A hierarchy of BC phenotypes defined by HR and Her2 status exists with progressively worse disease outcomes by category. n Key Words: breast cancer, estrogen receptor, her-2 neu, survival, triple negative Hormone receptor and Her2 neu (Her2) analysis are two characteristics commonly used in current clinical practice to gauge breast cancer prognosis and identify appropriate treatment options. Recent studies have suggested differential survival in breast cancer patients based on the presence of specific combinations of estrogen receptor (ER) and progesterone receptor (PgR) status (1 3). Patients with both ERand PgR-positive status have the best reported outcomes whether treated with tamoxifen or not (1,3). In 1987, Slamon et al. (4) reported a worse prognosis among Her2-positive breast cancers compared with Her2-negative tumors. With targeted treatment in the form of trastuzumab (herceptin) for metastatic disease approved by the FDA in November 1998 and for Address correspondence and reprint requests to: Henry G. Kaplan, MD, Swedish Medical Center, Swedish Cancer Institute, 1221 Madison Street, Seattle, WA 98104, USA, or hank.kaplan@swedish.org. Supported by the Kaplan Research Fund. Our study is an original research study, part of which was presented as a poster at the San Antonio Breast Cancer Symposium, December ª 2008 Wiley Periodicals, Inc., X/08 The Breast Journal, Volume 14 Number 5, adjuvant treatment in 2006, testing for Her2 has become part of routine clinical practice (5,6). In a cohort study of breast cancer patients from North Carolina oversampled for premenopausal and African American women, Carey et al. (7) found the shortest survival among Her2+ ER) and basal-like subtypes compared with other HR and growth factor receptor subtypes. Gago et al. (8) found a lower disease-free survival rate among hormone receptor (HR)-positive Her2 neu-positive patients compared with HR-positive Her2 neu-negative patients, all treated with tamoxifen. More recent studies have identified a prognostic concordance between gene markers, other tumor markers, and triple negative (TN) status, indicating a distinct biologic nature of the TN phenotype (9 11). Our objective is to identify distinct subgroups of primary breast cancer using ER, PgR, and Her2 neu status and to compare presentation, treatment, and outcomes in a cohort of breast cancer patients prior to widespread use of trastuzumab for metastatic disease or adjuvant chemotherapy. In particular, we are interested in differential survival and recurrence between TN patients, ER) PgR) Her2 neu), and ER) PgR)
2 Survival in Triple Negative Breast Cancer 457 Her2 neu+ patients compared with their ER+ PgR+ counterparts, correcting for presentation characteristics to determine if phenotypic subtype carries a differential risk of it s own. METHODS A breast cancer registry of all patients seen at our institution was created in 1990 containing detailed information on diagnosis, staging, surgery, chemotherapy, radiation therapy, tumor markers, and follow-up status. Registry follow-up is updated on an annual basis by a certified cancer registrar with information on recurrence, subsequent treatment, and vital status, current through Vital and disease status information is obtained from chart review if the patient is still seen at the Institution or through physiciandirected follow-up letter if follow-up care is provided elsewhere. Patients not under the care of a managing physician are contacted by mail using an Institutional Review Board (IRB) approved letter from their diagnosing physician requesting annual follow-up information. If no response is received, the institution s cancer registry and the Seattle-Puget Sound Surveillance Epidemiology and End Results cancer registry are reviewed for vital and disease status. Only IRB approved methods were used for patient follow-up and data was input and stored in a password protected HIPAA compliant database. All analyses were conducted using de-identified data as per IRB and HIPAA guidelines. This project was reviewed and approved by the IRB at our community-based regional cancer center. The cohort of 2338 patients TNM [primary tumor (T), regional node (N), distant metastasis (M)] breast cancer stage I IV [Americal Joint Committee on Cancer 6 (AJCC 6)], excluding inflammatory breast cancers (n = 65), was diagnosed between 1998 and 2003 and updated annually for recurrence and or vital status, current as of (12). Her2 neu tumor marker testing was carried out on the majority of the patient population in 1998 (64%) and by 2001, 94% of all breast cancer patients had Her2 neu testing conducted on them. Out of the 2338 patients, 2019 in our cohort were tested for Her2 neu (86%). Her2 neu testing on tissue samples was carried out at various local pathology laboratories by immunohistochemistry and the results were abstracted by chart review for entry into the registry. Her2 neu tests were chart reported in three ways and are as follows: (i) 0, 1+ = negative, 2+ = indeterminate, and 3+ = positive; (ii) as percentages <10% = negative = 0)1+, 10% to 30% = equivocal = 2+, and >30% = positive=3+; and (iii) as negative, weakly positive, and positive. Patients with Her2 neu test results reported as weak-positive, 2+, or indeterminate without fluorescence in situ hybridization (FISH) testing conducted for confirmation were excluded from the analysis (n = 168) leaving a cohort of 1851 patients. FISH testing was recorded in the chart on (7.1%) of these patients. ER and PgR testing was conducted at various local laboratories with a single report format of positive, negative, or borderline test results. Of the 1851 Her2 neu tested patients, 60 were excluded because they were not tested for HR status or had ER or PgR test results reported as borderline in the chart. We restricted our comparative and survival analysis to the cohort of HR concordant (ER+ PgR+ and ER) PgR)) pairs with conclusive Her2 neu tests (n = 1550). In survival analysis using Kaplan Meier plots and log rank pairwise category comparisons, ER+ PgR), ER) PgR+, and ER) PgR) were all significantly different from ER+ PgR+. However, the ER+ PgR), ER) PgR+, and ER) PgR) groups were not significantly different from each other (data not presented). Therefore to evaluate the independent effect of Her2 neu status in combination with HR status, we excluded discordant ER PgR pairs, ER+ PgR) (n = 224), and ER) PgR+ (n = 17) from the analysis. The resulting cohort consisted of females aged years diagnosed with primary invasive breast cancer, with a minimum of 2 years follow-up (n = 1550). Bivariate analyses of significant differences by HR her2-neu status were performed using Pearson chi-square tests for categorical variables and t-tests for continuous variables (F statistic). For ordinal categorical variables in 2 by k table analysis by detection method, a chi-square test for trend was used with one degree of freedom. All p-values were two-sided. The Kaplan Meier method was used to create survival curves and calculate 5-year survival rates. Overall survival (OS) was defined as time to death from any cause, disease-specific survival (DSS) was defined as time to death from breast cancer and relapse-free survival (RFS) was defined as the time to first recurrence of breast cancer, local, regional, distant, or combination. DSS is defined as the percentage of people in a study who have survived a particular disease since diagnosis or treatment. For the disease-specific and RFS analysis, stage IV tumors were excluded. Breast cancer specific death was assigned as the endpoint if
3 458 kaplan and malmgren the patient died without ever being cancer-free or if disease had recurred and was present at death. Patients who died of other causes without breast cancer present at death were not counted as a breast cancer specific death. Cox regression analysis was used to estimate crude and adjusted hazard ratios and their 95% confidence intervals (CIs) for OS, DSS, and RFS. The Cox model regression by HR Her2 category was run unadjusted and adjusted for age, race, treatment (adjuvant chemotherapy and or radiation), and AJCC 6 TNM stage. spss version (SPSS Inc., Chicago, IL, USA) was used for all statistical analysis (13). Of the Stage I II patients, 14% of the TP patients (n = 19) and 19% of the HR) Her2+ patients (n = 18) (total = 37) received adjuvant trastuzumab treatment. Five of these patients were part of experimental protocols and the rest were not. Analysis was conducted with and without these patients in the equations to assess the impact of trastuzumab on outcome. RESULTS In our cohort of 1550 women diagnosed with breast cancer between 1998 and 2003, the mean age was years with a range from 21 to 88 years. Eightyeight percent were white, 2% were black, 7% were Asian, and 3% were other or unknown. Sixty percent were diagnosed between 2001 and The majority of patients were ER+ PgR+ Her2) (HR+ Her2)) (n = 1134, 73%), 138 patients were ER+ PgR+ Her2+ (triple positive, TP) (9%), 183 were ER) PgR) Her2) (TN) (12%), and 95 patients were ER) PgR) Her2+ (HR) Her2+) (6%). Less than half of women aged 21 to 39 years had HR+ Her2) tumors (44.5%) with 14% TP, 27% TN, and 15% HR) Her2+ marker status tumors (Pearson v 2 = 86.27, p < 0.001). Conversely, the majority of women aged years had HR+ Her2) tumors (81%) (Fig. 1). The cohort was predominantly white with the highest percentage of black women in the TN group (7%) (Pearson v 2 = 34.79, p < 0.001). Results are presented in Table 1. Significantly more of the TP (51%), TN (61%), and HR) Her2+ (57%) women had patient-detected breast cancer compared with the HR+ Her2) (35%) group (Pearson v 2 = 66.16, p < 0.001). More of the HR+ Her2) patients had lobular and ductal lobular carcinoma than the other three groups. The TN and HR) Her2+ women had significantly more unusual histologic types with six metaplastic tumors in the TN Figure 1. HR Her2 status by age. group. The TN group had the largest mean tumor size (2.79 cm, 95% CI = 2.43, 3.15) compared with HR+ Her2) (1.88 cm, 95% CI = 1.79, 1.97), TP (2.50 cm, 95% CI = 2.14, 2.85), and HR) Her2+ (2.65 cm, 95% CI = 2.23, 3.07) (F statistic = 20.44, p < 0.001). HR+ Her2) patients had the highest percentage of tumors less than or equal to 2 cm (73%), with 57% in the TP group, 51% in the TN group, and 47% in the HR) Her2+ group (Table 1). The HR+ Her2) group had the largest percentage of TNM stage I cases (55%) with progressively fewer in the TP (43%), TN (39%), and HR) Her2+ (30%) groups (Table 1). The TN group had the most patients with high histologic and nuclear grade and high Bloom-Richardson scores, 92%, 80%, and 86%, respectively, followed by the HR) Her2+ group, TP group, and HR+ Her2) group. The HR) Her2+ group had the highest mean number of positive lymph nodes, 2.17, followed by TN, 1.50, TP, 1.37, and HR+ Her2), 1.15 (F statistic = 3.32, p = 0.019). The HR+ Her2) and the TN groups were equally unlikely to have one or more positive lymph nodes, 36% and 35% respectively, with a higher percentage of one or more positive nodes in the TP (44%) and HR) Her2+ (53%) groups. Triple positive (TP) (41%), TN (33%), and HR) Her2+ (36%) women were significantly more likely to have modified radical mastectomies than the HR+ Her2) women (27%) (Pearson v 2 = 23.90, p = 0.004). Thirty-seven percent of the HR+ Her2) women received both radiation and chemotherapy treatment compared with the TP (61%), the TN (73%), and the HR) Her2+ patients (84%) (Pearson v 2 = , p < 0.001). Vital status at follow-up was significantly different by HR Her2 category. With a minimum of 2 years
4 Survival in Triple Negative Breast Cancer 459 Table 1. Descriptive Characteristics by Hormone Receptor (HR) Her-2 neu Status (n = 1550) HR+ Her2) (col. %) HR+ Her2+ (col. %) HR) Her2) (col. %) HR) Her2+ (col. %) Variable n = 1134 n = 138 n = 183 n =95 Chi-square p-value Race White 1012 (89%) 116 (84%) 156 (85%) 78 (82%) <0.001 Black 14 (1%) 3 (2%) 12 (7%) 2 (2%) Other* 108 (10%) 19 (14%) 15 (8%) 15 (16%) Menopausal status Post 750 (67%) 75 (56%) 91 (51%) 48 (51%) <0.001 Detection method Mammography 636 (57%) 57 (42%) 56 (31%) 31 (33%) <0.001 Patient 395 (35%) 69 (51%) 111 (61%) 53 (57%) Physician 87 (8%) 9 (7%) 15 (8%) 9 (8%) Histology Ductal 860 (76%) 121 (88%) 166 (91%) 87 (92%) <0.001 Lobular 130 (12%) 6 (4%) 5 (3%) 0 (0%) Ductal lobular 84 (7%) 4 (4%) 1 (0.5%) 1 (0.5%) Other mixed types 60 (5%) 7 (5%) 11 (6%) 7 (7%) T stage T1: 2 cm 828 (73%) 78 (57%) 93 (51%) 45 (47%) <0.001 TNM stage (12) I 619 (55%) 59 (43%) 72 (39%) 28 (30%) <0.001 II 398 (35%) 56 (41%) 73 (40%) 45 (47%) III 97 (9%) 19 (14%) 31 (17%) 18 (19%) IV 20 (2%) 4 (3%) 7 (4%) 4 (4%) Histologic grade Grade 1 low 138 (12%) 7 (5%) 1 (0.6%) 3 (3%) <0.001 Grade 2 int 362 (33%) 38 (29%) 13 (7%) 8 (9%) Grade 3 high 615 (55%) 87 (66%) 165 (92%) 79 (88%) Nuclear grade Grade 1 low 127 (11%) 8 (6%) <0.001 Grade 2 int 772 (69%) 67 (50%) 36 (20%) 20 (22%) Grade 3 high 217 (19%) 60 (44%) 141 (80%) 72 (78%) B R score Grade (36%) 14 (12%) 3 (2%) 1 (1%) <0.001 Grade (48%) 61 (52%) 20 (12%) 18 (22%) Grade (16%) 43 (36%) 146 (86%) 64 (77%) int, intermediate. *Other: asian, hispanic, and native american; B R scores, Bloom Richardson scores. Other mixed types: colloid mucinous, tubular, cancer not otherwise specified, ductal carcinoma in situ with microinvasion, papillary, medullary, and metaplastic. Table 2. Outcomes by Hormone Receptor (HR) Her-2 neu Status (n = 1550) HR+ Her2) (col. %) HR+ Her2+ (col. %) HR) Her2) (col. %) HR) Her2+ (col. %) Variable n = 1134 n = 138 n = 183 n =95 Chi-square p-value Outcomes Vital status Alive NED 1038 (92%) 122 (88%) 144 (78%) 74 (78%) <0.001 Alive w this Ca 36 (3%) 4 (3%) 10 (6%) 5 (5%) Alive w other Ca 9 (0.8%) 1 (0.7%) 3 (2%) 1 (1%) Expired NED 23 (2%) 2 (1%) 4 (2%) 2 (2%) Expired w this Ca 22 (2%) 8 (6%) 19 (10%) 13 (14%) Expired w other Ca 6 (0.5%) 1 (0.7%) 4 (2%) 0 Recurrence type None 1074 (96%) 123 (91%) 153 (85%) 72 (77%) <0.001 Local regional 6 (0.5%) 2 (1.5%) 5 (3%) 4 (4%) Distant 39 (3.5%) 10 (7.5%) 23 (13%) 15 (16%) Combination 1 (0.1%) (3%) NED, no evidence of disease; Ca, cancer; col, column.
5 460 kaplan and malmgren follow-up for alive patients, 91% of the HR+ Her2) group were alive no evidence of disease, followed by 88% of the TP, 78% of the TN, and 77% of the HR) Her2+ women. The HR) Her2+ patients had the highest rate of death because of disease (14%), followed by 10% among the TN, 6% among the TP, and 2% among the HR+ Her2). The rate of distant recurrence was 17% in the HR) Her2+ group, 13% in the TN group, 7% in the TP group, and 3% in the HR+ Her2) group. There were fewer cases of local or regional recurrence and overall recurrence was highest in the HR) Her2+ group (24%), followed by 16% in the TN group, 8.4% in the TP group, and 3.3% in the HR+ Her2) group (Pearson v 2 = , p < 0.001). Outcome results are presented in Table 2. For OS using all cause mortality as the endpoint, the HR+ Her2) patients (5-year OS = 94%) and TP patients (5-year OS = 91%) had significantly better survival than the HR) Her2+ (5-year OS = 81%) and TN (5-year OS = 81%) patients (n = 1550). At 5 years, the HR+ (HR+ Her2), TP) and HR) (TN, HR) Her2+) groups were significantly different but there was no significant difference in OS comparing HR+ Her2) to TP and TN to HR) Her2+ groups by pairwise log rank comparisons (Fig. 2). For DSS with mortality from this cancer as the outcome and excluding TNM stage IV patients, DSS was 98% for the HR+ Her2) group, 95% for the TP group, 88% for the TN group, and 86% for the HR) Her2+ group (overall log rank test = 36.92, p < 0.001) (n = 1515). By log rank pairwise comparisons, the HR+ Her2) had significantly better DSS than the TN and HR) Her2+ groups but the same DSS as the TP group (Fig. 2). Relapse-free survival with local, regional, or distant relapse as the outcome and excluding the TNM stage IV patients were the following: HR+ Her2), 95%; TP, 89%; TN, 84%, and HR) Her2+, 76% (Fig. 2) (n = 1515). The HR) Her2+ group had worse RFS than the HR+ Her2) and TP groups but TN patients were only significantly different compared with the HR+ Her2) group (Fig. 2). When adjuvant herceptin-treated patients were removed from the analysis (n = 34), the HR) Her2+ group RFS dropped from 76 to 73%. In unadjusted models, TP status was not associated with OS (HR = 1.42, 95% CI = 0.74, 2.72) or disease-free survival (HR = 2.31, 95% CI = 0.91, 5.83) but was associated with RFS (HR = 2.10, 95% Figure 2. Kaplan Meier plots. CI = 1.11, 3.97) compared to the reference group (HR+ Her2)) (Table 3). TN status was associated with OS (HR = 3.21, 95% CI = 2.02, 5.12), DSS (HR = 4.89, 95% CI = 2.43, 9.83), and RFS (HR = 3.29, 95% CI = 1.99, 5.44) compared to the reference group. HR) Her2+ status was associated
6 Survival in Triple Negative Breast Cancer 461 Table 3. Cox Regression Analysis of Relapse- Free, Disease-Specific, and Overall Survival by Hormone Receptor (HR) Her2 neu Status (n = 1550) Hormone receptor Her2 neu status* Unadjusted hazard ratio (95% CI) p-value Adjusted hazard ratio (95% CI) p-value Overall survival (n = 1550) TP 1.42 (0.74, 2.72) (0.85, 3.22) TN 3.21 (2.02, 5.12) < (2.48, 7.40) <0.001 HR) Her (1.56, 4.96) < (2.06, 8.10) <0.001 Disease-specific survival (n = 1515) TP 2.31 (0.91, 5.83) (0.98, 6.64) TN 4.89 (2.43, 9.83) < (2.11, 10.48) <0.001 HR) Her (2.86, 13.00) < (3.58, 20.68) <0.001 Relapse-free survival (n = 1515) TP 2.10 (1.11, 3.97) (1.02, 3.81) TN 3.29 (1.99, 5.44) < (1.42, 4.23) HR) Her (3.08, 9.04) < (2.47, 8.06) <0.001 TP, triple positive; TN, triple negative. *HR+ Her2) subtype was used as the reference category; model adjusted for age, race, treatment, and TNM stage. Excluding TNM stage IV patients. with OS (HR = 2.78, 95% CI = 1.56, 4.96), DSS (HR = 6.10, 95% CI = 2.86, 13.00), and RFS (HR = 5.28, 95% CI = 3.08, 9.04) compared to the reference group (Table 3). In Cox regression analysis age, race, treatment (adjuvant chemotherapy, radiation therapy, or combined chemotherapy and radiation therapy), TNM stage (AJCC 6), and HR Her2 neu category, were significant predictors of any cause mortality. In the adjusted model, (i) TP status was not associated with OS (hazard ratio = 1.65, 95% CI = 0.85, 3.22) or DSS (hazard ratio = 2.55, 95% CI = 0.98, 6.64), but was associated with RFS (hazard ratio = 1.98, 95% CI = 1.02, 3.81) compared to HR+ Her2) patients (reference group); (ii) TN status was associated with OS (hazard ratio = 4.29, 95% CI = 2.48, 7.40), DSS (hazard ratio = 4.70, 95% CI = 2.11, 10.48), and RFS (hazard ratio = 2.45, 95% CI = 1.42, 4.23) compared to the reference group; and (iii) HR) Her2+ status was associated with OS (hazard ratio = 4.09, 95% CI = 2.06, 8.10), DSS (hazard ratio = 8.61, 95% CI = 3.58, 20.68), and RFS (hazard ratio = 4.46, 95% CI = 2.47, 8.06) compared with the reference group (Table 3) (Fig. 3). DISCUSSION A linear trend was observed in prognostic characteristics by HR Her2 neu-defined phenotypic subtype with a higher percentage of favorable characteristics in the HR+ Her2) and progressively less favorable Figure 3. Hazard function graphs. profiles in each subsequent phenotypic subtype from HR+ Her2) to HR+ Her2+ to HR) Her2) to HR) Her2+. Variables following this trend included age, stage, histologic, and nuclear grade. A reverse progression was observed by group for treatment with the HR) Her2+ group receiving the most aggressive treatment followed by the TN, TP, and HR+ Her2) group. Likewise for outcomes, the HR+ Her2) group was least likely to die of disease and least likely to have a recurrence followed by the TP, TN, and
7 462 kaplan and malmgren HR) Her2+ groups. OS was significantly better for HR-positive breast cancer [HR+ Her2) and HR+ Her2+ (TP)] than for HR-negative breast cancer (HR) Her2) (TN) and HR) Her2+). The disease-specific and relapse-free risk patterns by HR and Her2 groupings mirrored the severity levels observed by prognostic characteristics with the best survival among the HR+ Her2) group followed by TP, TN, and the HR) Her2+ group. Likewise, the Cox proportional hazards model results display a pattern of progressively worse risk of disease specific mortality and disease recurrence for the TP, TN, and HR) Her2+ groups compared with the HR+ Her2) group adjusted for age, race, treatment, and stage. The strengths of our study include the comprehensive nature of the registry database with patient presentation characteristics, treatment and outcomes, and complete ascertainment of patient status at regular follow-up intervals. The availability of a registry cohort of breast cancer patients with complete follow-up and Her2 neu test results present a unique opportunity to study the presentation characteristics and outcomes associated with Her2 neu-defined disease. Her2/neu testing was done on 94% or more of breast cancer patients from 2000 to 2003 with lower testing rates in 1998 and 1999 when the test first became available. Women in our cohort not tested for Her2/neu were more likely to be ER-positive and TNM stage I (data not presented). The result of a lower rate of testing among ER-positive and stage I patients would be a reduced representation of lower stage, more benign disease in our cohort primarily in the reference group of HR+ Her2) patients. The small admixture of trastuzumab patients was addressed in two ways to correct for potential confounding. One way was to conduct the survival analysis with and without trastuzumabtreated patients, and two to add chemotherapy treatment to the hazard analysis model. Our experience, which encompasses the pre-herceptin era, confirms the findings of others that Her2- positive disease has a worse prognosis than Her2-negative disease (4,14). Recent studies have shown that treatment with trastuzumab appears to eliminate the disparity in outcomes between these two groups (6,15). Our findings indicate that HR status is a more powerful predictor of outcome than Her2 neu status. Better outcomes in the HR-positive patients are partly because of better response to more specific multimodality treatment of disease more often discovered at an early stage by mammography. Her2 status is not as strong a distinguishing prognostic indicator but in combination with HR status, identifies a progressively worse outcome with each change in HR and Her2 neu status in spite of aggressive treatment administration. We have described a hierarchical model of breast cancer phenotypic subtypes based on HR and Her- 2 neu status that has prognostic value for clinical evaluation of patient risk. The differential presentation of more aggressive phenotypes in young women suggests a different biologic mechanism may be at work creating a situation in which patients present with more advanced disease that is less often detected by mammography (16). Hopefully, further study of the biology of more aggressive phenotypes like TN HR Her-2 neu tumors will lead to improved methods of diagnosis and better treatment protocols. Acknowledgments The authors wish to gratefully acknowledge the work of Mary Atwood, the Swedish Cancer Institute s breast cancer registrar for her invaluable assistance in collecting the data for this study. REFERENCES 1. Arpino G, Weiss H, Lee AV, et al. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 2005;97: Grann VR, Troxel AB, Zojwalla NJ, et al. Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma. Cancer 2005;103: Ouyang Y, Li D, Pater JL, et al. The importance of temporal effects in evaluating the prognostic impact of joint ERPR expression in premenopausal women with node-positive breast cancer. Breast Cancer Res Treat 2005;92: Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the Her-2 neu oncogene. Science 1987;235: Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344: Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353: Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA 2006;295: Gago FE, Fanelli MA, Ciocca DR. Co-expression of steroid hormone receptors (estrogen receptor a and or progesterone receptors) and her2 neu (c-erbb-2) in breast cancer: clinical outcome following tamoxifen-based adjuvant therapy. J Steroid Biochem Mol Biol 2006;98: Haffty BG, Yang Q, Reiss M, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early stage breast cancer. J Clin Oncol 2006;24:
8 Survival in Triple Negative Breast Cancer Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer. Cancer 2007;109: Fan C, Oh DS, Wessels L, et al. Concordance among geneexpression-based predictors for breast cancer. N Engl J Med 2006;355: American Joint Committee on Cancer Staging, 6th edn. New York, NY: Springer-Verlag, SPSS. SPSS for Windows, Release Chicago, IL, USA: SPSS, Perou CM, Sorlie T, Elsen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406: Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353: Kaplan HG, Malmgren JA. Disease specific survival in patient detected breast cancer. Clin Breast Cancer 2006;7:
SFMC Breast Cancer Site Study: 2011
SFMC Breast Cancer Site Study: 2011 Introduction Breast cancer is the most frequently diagnosed cancer among American women, except for skin cancers. It is the second leading cause of cancer death in women,
More informationThe effect of delayed adjuvant chemotherapy on relapse of triplenegative
Original Article The effect of delayed adjuvant chemotherapy on relapse of triplenegative breast cancer Shuang Li 1#, Ding Ma 2#, Hao-Hong Shi 3#, Ke-Da Yu 2, Qiang Zhang 1 1 Department of Breast Surgery,
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationClinical Features and Survival Analysis of T1mic, a, bn0m0 Breast Cancer
Original Articles Jpn J Clin Oncol 2012;42(6)471 476 doi:10.1093/jjco/hys046 Advance Access Publication 3 April 2012 Clinical Features and Survival Analysis of T1mic, a, bn0m0 Breast Cancer Junnan Li,
More informationJ Clin Oncol 24: by American Society of Clinical Oncology INTRODUCTION
VOLUME 24 NUMBER 36 DECEMBER 20 2006 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage Breast Cancer
More informationLocoregional treatment Session Oral Abstract Presentation Saulo Brito Silva
Locoregional treatment Session Oral Abstract Presentation Saulo Brito Silva Background Post-operative radiotherapy (PORT) improves disease free and overall suvivallin selected patients with breast cancer
More informationClinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer. Cheol Min Kang 2018/04/05
Abstract No.: ABS-0075 Clinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer 2018/04/05 Cheol Min Kang Department of surgery, University of Ulsan
More informationOutcomes of Trastuzumab Therapy for 6 and 12 Months in Indonesian National Health Insurance System Clients with Operable HER2-Positive Breast Cancer
DOI:10.22034/APJCP.2017.18.4.1151 Trastuzumab RESEARCH ARTICLE Outcomes of Trastuzumab Therapy for 6 and 12 Months in Indonesian National Health Insurance System Clients with Operable HER2-Positive Breast
More informationCarcinome du sein Biologie moléculaire. Thomas McKee Service de Pathologie Clinique Genève
Carcinome du sein Biologie moléculaire Thomas McKee Service de Pathologie Clinique Genève Pathology Diagnostic Prognostic information Predictive information The information provided depends on the available
More informationOnly Estrogen receptor positive is not enough to predict the prognosis of breast cancer
Young Investigator Award, Global Breast Cancer Conference 2018 Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer ㅑ Running head: Revisiting estrogen positive tumors
More informationNIH Public Access Author Manuscript Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2011 January 1.
NIH Public Access Author Manuscript Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2010 January ; 19(1): 144 147. doi:10.1158/1055-9965.epi-09-0807. Feasibility Study for Collection
More informationUK Interdisciplinary Breast Cancer Symposium. Should lobular phenotype be considered when deciding treatment? Michael J Kerin
UK Interdisciplinary Breast Cancer Symposium Should lobular phenotype be considered when deciding treatment? Michael J Kerin Professor of Surgery National University of Ireland, Galway and Galway University
More informationBasement membrane in lobule.
Bahram Memar, MD Basement membrane in lobule. Normal lobule-luteal phase Normal lobule-follicular phase Lactating breast Greater than 95% are adenocarcinomas in situ carcinomas and invasive carcinomas.
More informationTriple Negative Breast Cancer
Triple Negative Breast Cancer Prof. Dr. Pornchai O-charoenrat Division of Head-Neck & Breast Surgery Department of Surgery Faculty of Medicine Siriraj Hospital Breast Cancer Classification Traditional
More informationBreast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined
Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women Mortality rates though have declined 1 in 8 women will develop breast cancer Breast Cancer Breast cancer increases
More informationBreast Cancer. Saima Saeed MD
Breast Cancer Saima Saeed MD Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women 1 in 8 women will develop breast cancer Incidence/mortality rates have declined Breast
More informationMaram Abdaljaleel, MD Dermatopathologist and Neuropathologist University of Jordan, School of Medicine
Maram Abdaljaleel, MD Dermatopathologist and Neuropathologist University of Jordan, School of Medicine The most common non-skin malignancy of women 2 nd most common cause of cancer deaths in women, following
More informationSCIENCE CHINA Life Sciences
SCIENCE CHINA Life Sciences RESEARCH PAPER April 2013 Vol.56 No.4: 335 340 doi: 10.1007/s11427-013-4435-y Risk factors of recurrence in small-sized, node negative breast cancer in young women: a retrospective
More informationCarcinoma mammario: le istologie non frequenti. Valentina Guarneri Università di Padova IOV-IRCCS
Carcinoma mammario: le istologie non frequenti Valentina Guarneri Università di Padova IOV-IRCCS Histological diversity of breast adenocarcinomas Different histological types are defined according to specific
More informationHEALTH CARE DISPARITIES. Bhuvana Ramaswamy MD MRCP The Ohio State University Comprehensive Cancer Center
HEALTH CARE DISPARITIES Bhuvana Ramaswamy MD MRCP The Ohio State University Comprehensive Cancer Center Goals Understand the epidemiology of breast cancer Understand the broad management of breast cancer
More informationHeather M. Gage, MD, Avanti Rangnekar, Robert E. Heidel, PhD, Timothy Panella, MD, John Bell, MD, and Amila Orucevic, MD, PhD
HER2 POSITIVE BREAST CARCINOMA IN THE PRE AND POST ADJUVANT ANTI-HER-2 THERAPY ERA: A SINGLE ACADEMIC INSTITUTION EXPERIENCE IN THE SETTING OUTSIDE OF CLINICAL TRIALS Heather M. Gage, MD, Avanti Rangnekar,
More informationProperties of Synchronous Versus Metachronous Bilateral Breast Carcinoma with Long Time Follow Up
DOI:http://dx.doi.org/10.7314/APJCP.2015.16.12.4921 Properties of Synchronous Versus Metachronous Bilateral Breast Carcinoma with Long Time Follow Up RESEARCH ARTICLE Properties of Synchronous Versus Metachronous
More informationBreast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience
Breast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience Curzon M, Curzon C, Heidel RE, Desai P, McLoughlin J, Panella T, Bell
More informationDoes HER2/neu overexpression in breast cancer influence adjuvant chemotherapy and hormonal therapy choices by Ontario physicians? A physician survey
MYERS et al. ORIGINAL ARTICLE Does HER2/neu overexpression in breast cancer influence adjuvant chemotherapy and hormonal therapy choices by Ontario physicians? A physician survey J.A. Myers MD FRCPC, G.
More informationChapter 5: Epidemiology of MBC Challenges with Population-Based Statistics
Chapter 5: Epidemiology of MBC Challenges with Population-Based Statistics Musa Mayer 1 1 AdvancedBC.org, Abstract To advocate most effectively for a population of patients, they must be accurately described
More informationLong term survival study of de-novo metastatic breast cancers with or without primary tumor resection
Long term survival study of de-novo metastatic breast cancers with or without primary tumor resection Dr. Michael Co Division of Breast Surgery Queen Mary Hospital The University of Hong Kong Conflicts
More informationTime to Start Adjuvant Systemic Treatment in Breast Cancer; a Retrospective Cohort Study
Cancer and Clinical Oncology; Vol. 6, No. 2; 2017 ISSN 1927-4858 E-ISSN 1927-4866 Published by Canadian Center of Science and Education Time to Start Adjuvant Systemic Treatment in Breast Cancer; a Retrospective
More informationClinico- Pathological Features And Out Come Of Triple Negative Breast Cancer
Clinico- Pathological Features And Out Come Of Triple Negative Breast Cancer Dr. HassanAli Al-Khirsani, MBChB, CABM, F.I.C.M.S AL-Sadder teaching hospital, oncology unit Dr. Nasser Ghaly Yousif, MBChB,G.P.
More informationTaxotere * and carboplatin plus Herceptin (trastuzumab) (TCH): the first approved non-anthracycline Herceptin-containing regimen 1
Important data from BCIRG 006 Taxotere * and carboplatin plus Herceptin (trastuzumab) (TCH): the first approved non-anthracycline Herceptin-containing regimen 1 in the adjuvant treatment of HER2+ breast
More informationConcordance among Gene-Expression Based Predictors for Breast Cancer
The new england journal of medicine original article Concordance among Gene-Expression Based Predictors for Breast Cancer Cheng Fan, M.S., Daniel S. Oh, Ph.D., Lodewyk Wessels, Ph.D., Britta Weigelt, Ph.D.,
More informationMolecular subtypes in patients with inflammatory breast cancer; A single center experience
JBUON 05; 0(): 35-3 ISSN: 0-065, online ISSN: 4-63 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Molecular subtypes in patients with inflammatory breast cancer; A single center experience
More informationClinical pathological and epidemiological study of triple negative breast cancer
International Journal of Research in Medical Sciences Ajay A et al. Int J Res Med Sci. 217 Jun;5(6):2657-2661 www.msjonline.org pissn 232-71 eissn 232-12 Original Research Article DOI: http://dx.doi.org/1.1823/232-12.ijrms2172465
More informationSurvival of Triple Negative versus Triple Positive Breast Cancers: Comparison and Contrast
10.14456/apjcp.2016.191/APJCP.2016.17.8.3911 Survival of Triple Negative and Triple Positive Breast Cancers RESEARCH ARTICLE Survival of Triple Negative versus Triple Positive Breast Cancers: Comparison
More informationBreast-Conserving Therapy for Triple-Negative Breast Cancer
Research Original Investigation PACIFIC COAST SURGICAL ASSOCIATION Breast-Conserving Therapy for Triple-Negative Breast Cancer Alexandra Gangi, MD; Alice Chung, MD; James Mirocha, MS; Douglas Z. Liou,
More informationChapter 13 Cancer of the Female Breast
Lynn A. Gloeckler Ries and Milton P. Eisner INTRODUCTION This study presents survival analyses for female breast cancer based on 302,763 adult cases from the Surveillance, Epidemiology, and End Results
More informationImmunohistochemical classification of breast tumours
Immunohistochemical classification of breast tumours Workshop in Diagnostic Immunohistochemistry September 19 th - 21 th 2018 Anne-Vibeke Lænkholm Department of Surgical Pathology, Zealand University Hospital,
More informationQ&A. Fabulous Prizes. Collecting Cancer Data: Breast 4/4/13. NAACCR Webinar Series Collecting Cancer Data Breast
Collecting Cancer Data Breast NAACCR 2012 2013 Webinar Series Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching this webinar
More informationEGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer
ONCOLOGY REPORTS 21: 413-417, 2009 413 EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer HIROKO NOGI 1, TADASHI KOBAYASHI 2, MASAFUMI SUZUKI 3, ISAO TABEI
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/55957 holds various files of this Leiden University dissertation Author: Dekker T.J.A. Title: Optimizing breast cancer survival models based on conventional
More informationBioscore: A Staging System for Breast Cancer Patients that Reflects the Prognostic Significance of Underlying Tumor Biology
Ann Surg Oncol DOI./s-7-9-x ORIGINAL ARTICLE BREAST ONCOLOGY Bioscore: A Staging System for Breast Cancer Patients that Reflects the Prognostic Significance of Underlying Tumor Biology Elizabeth A. Mittendorf,
More informationMy Personalized Breast Cancer Worksheet
My Personalized Breast Cancer Worksheet KNOW For Early-Stage Breast Cancer. No Questions. Only Results. No two tumors are alike. What are the characteristics of your breast cancer and how will that effect
More informationLong-Term Survival Analysis of Korean Breast Cancer Patients at a Single Center: Improving Outcome Over Time
Original Article http://dx.doi.org/1.339/ymj.1.55.5.117 pissn: 513-579, eissn: 197-37 Yonsei Med J 55(5):117-1195, 1 Long-Term Survival Analysis of Korean Breast Cancer Patients at a Single Center: Improving
More informationBreast cancer: Molecular STAGING classification and testing. Korourian A : AP,CP ; MD,PHD(Molecular medicine)
Breast cancer: Molecular STAGING classification and testing Korourian A : AP,CP ; MD,PHD(Molecular medicine) Breast Cancer Theory: Halsted Operative breast cancer is a local-regional disease The positive
More information4/13/2010. Silverman, Buchanan Breast, 2003
Tailoring Breast Cancer Treatment: Has Personalized Medicine Arrived? Judith Luce, M.D. San Francisco General Hospital Avon Comprehensive Breast Care Center Outline First, treatment of DCIS Sorting risk
More informationBreast Cancer. Excess Estrogen Exposure. Alcohol use + Pytoestrogens? Abortion. Infertility treatment?
Breast Cancer Breast Cancer Excess Estrogen Exposure Nulliparity or late pregnancy + Early menarche + Late menopause + Cystic ovarian disease + External estrogens exposure + Breast Cancer Excess Estrogen
More informationHealth Disparities Advances in Breast Cancer Treatment. Jo Anne Zujewski April 27, 2009
Health Disparities Advances in Breast Cancer Treatment Jo Anne Zujewski April 27, 2009 Disclaimer Breast Cancer Incidence 1994-2003 Breast Cancer Mortality 1994-2003 Access to Care Comorbidity Biology
More informationoriginal articles introduction
Annals of Oncology 19. List HJ, Reiter R, Singh B et al. Expression of the nuclear coactivator AIB1 in normal and malignant breast tissue. Breast Cancer Res Treat 2001; 68: 21 28. 20. Jansson A, Delander
More informationProsigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY
Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY Methodology The test is based on the reported 50-gene classifier algorithm originally named PAM50 and is performed on the ncounter Dx Analysis System
More informationProsigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY
Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY GENE EXPRESSION PROFILING WITH PROSIGNA What is Prosigna? Prosigna Breast Cancer Prognostic Gene Signature Assay is an FDA-approved assay which provides
More informationRace is not a factor in overall survival in patients with triple negative breast cancer: a retrospective review
Starlard-Davenport et al. SpringerPlus 2013, 2:516 a SpringerOpen Journal RESEARCH Open Access Race is not a factor in overall survival in patients with triple negative breast cancer: a retrospective review
More informationP atients with primary breast cancer have an increased risk of developing contralateral breast cancer1. When
OPEN SUBJECT AREAS: BONE METASTASES BREAST CANCER Received 23 July 2013 Accepted 19 August 2013 Published 5 September 2013 Correspondence and requests for materials should be addressed to C.W.D. (ducaiwen@
More informationBreast cancer presents a major risk to American. Cancer recurrence and survival in patients with early-stage triple-negative breast cancer
Original Research Cancer recurrence and survival in patients with early-stage triple-negative breast cancer Neal P. Christiansen, MD, 1 Lei Chen, MD, PhD, 2 James Gilmore, DPharm, 3 and Stephen Szabo,
More informationCase Scenario 1. 2/15/2011 The patient received IMRT 45 Gy at 1.8 Gy per fraction for 25 fractions.
Case Scenario 1 1/3/11 A 57 year old white female presents for her annual mammogram and is found to have a suspicious area of calcification, spread out over at least 4 centimeters. She is scheduled to
More informationIntro to Cancer Therapeutics
An Intro to Cancer Therapeutics Christopher R. Chitambar, MD Professor of Medicine Division of Hematology & Oncology Froedtert and Medical College of Wisconsin Clinical Cancer Center cchitamb@mcw.edu Intro
More informationClaudin-4 Expression in Triple Negative Breast Cancer: Correlation with Androgen Receptors and Ki-67 Expression
Claudin-4 Expression in Triple Negative Breast Cancer: Correlation with Androgen Receptors and Ki-67 Expression Mona A. Abd-Elazeem, Marwa A. Abd- Elazeem Pathology department, Faculty of Medicine, Tanta
More informationBreast Cancer? Breast cancer is the most common. What s New in. Janet s Case
Focus on CME at The University of Calgary What s New in Breast Cancer? Theresa Trotter, MD, FRCPC Breast cancer is the most common malignancy affecting women in Canada, accounting for almost a third of
More informationBy KAREN HUI LI B.Sc., Brock University, A Thesis Submitted in Partial Fulfillment of the Requirements for the Degree of MASTER OF SCIENCE
Micrometastatic Node-Positive Breast Cancer: An Analysis of Survival Outcomes and Prognostic Impact of the Number of Positive Nodes and the Ratio of Positive to Excised Nodes in Comparison to Node-Negative
More informationA Study to Evaluate the Effect of Neoadjuvant Chemotherapy on Hormonal and Her-2 Receptor Status in Carcinoma Breast
Original Research Article A Study to Evaluate the Effect of Neoadjuvant Chemotherapy on Hormonal and Her-2 Receptor Status in Carcinoma Breast E. Rajesh Goud 1, M. Muralidhar 2*, M. Srinivasulu 3 1Senior
More informationBreastScreen Aotearoa Annual Report 2015
BreastScreen Aotearoa Annual Report 2015 EARLY AND LOCALLY ADVANCED BREAST CANCER PATIENTS DIAGNOSED IN NEW ZEALAND IN 2015 Prepared for Ministry of Health, New Zealand Version 1.0 Date November 2017 Prepared
More informationTable S2. Expression of PRMT7 in clinical breast carcinoma samples
Table S2. Expression of PRMT7 in clinical breast carcinoma samples (All data were obtained from cancer microarray database Oncomine.) Analysis type* Analysis Class(number sampels) 1 2 3 4 Correlation (up/down)#
More informationEditorial Process: Submission:11/30/2017 Acceptance:01/04/2019
RESEARCH ARTICLE Editorial Process: Submission:11/30/2017 Acceptance:01/04/2019 in Non-Metastatic Triple-Negative Breast Cancer O Al jarroudi*, A Zaimi, S A Brahmi, S Afqir Abstract Introduction: Triple-negative
More informationContents 1 The Windows of Susceptibility to Breast Cancer 2 The So Called Pre-Neoplastic Lesions and Carcinoma In Situ
Contents 1 The Windows of Susceptibility to Breast Cancer... 1 1.1 Introduction... 1 1.2 Risk Factor and Etiological Agents... 2 1.3 The Concept of the Windows of Susceptibility to Carcinogenesis... 5
More informationAnnals of Breast Cancer. MedDocs Publishers. Open Access Research Article. Quintyne KI 1,2* ; Woulfe B 3 ; Coffey JC 2,4 ; Gupta RK 2,3
Long-term outcome data for patients with HER2- positive early-stage breast cancer treated with adjuvant trastuzumab: Benefit outside clinical trial setting Quintyne KI 1,2* ; Woulfe B 3 ; Coffey JC 2,4
More informationBreast Cancer Outcomes as Defined by the Estrogen Receptor, Progesterone Receptor, and Human Growth Factor Receptor-2 in a Multi-ethnic Asian Country
DOI 10.1007/s00268-015-3133-2 ORIGINAL SCIENTIFIC REPORT Breast Cancer Outcomes as Defined by the Estrogen Receptor, Progesterone Receptor, and Human Growth Factor Receptor-2 in a Multi-ethnic Asian Country
More informationUnderstanding and Optimizing Treatment of Triple Negative Breast Cancer
Understanding and Optimizing Treatment of Triple Negative Breast Cancer Edith Peterson Mitchell, MD, FACP Clinical Professor of Medicine and Medical Oncology Program Leader, Gastrointestinal Oncology Department
More informationThe Clinical Significance of. Triple-negative Phenotype on. Cancer Patients
The Clinical Significance of Triple-negative Phenotype on Prognosis of Young Age( 35) Breast Cancer Patients IM-KYUNG KIM Department of Medicine The Graduate School, Yonsei University The Clinical Significance
More informationSYSTEMIC THERAPY OPTIONS FOR BREAST CANCER IN 2014
SYSTEMIC THERAPY OPTIONS FOR BREAST Oncology Day 2014 CANCER IN 2014 Dr. Katherine Enright, M.D., M.P.H., F.R.C.P.(C) Katherine.enright@Trilliumhealthpartners.ca OBJECTIVES 1. Outline an approach to the
More informationDiseases of the breast (2 of 2) Breast cancer
Diseases of the breast (2 of 2) Breast cancer Epidemiology & etiology The most common type of cancer & the 2 nd most common cause of cancer death in women 1 of 8 women in USA Affects 7% of women Peak at
More informationOutcomes of patients with inflammatory breast cancer treated by breast-conserving surgery
Breast Cancer Res Treat (2016) 160:387 391 DOI 10.1007/s10549-016-4017-3 EDITORIAL Outcomes of patients with inflammatory breast cancer treated by breast-conserving surgery Monika Brzezinska 1 Linda J.
More informationComparison of Triple Negative Breast Cancer between Asian and Western Data Sets
2010 IEEE International Conference on Bioinformatics and Biomedicine Workshops Comparison of Triple Negative Breast Cancer between Asian and Western Data Sets Lee H. Chen Bioinformatics and Biostatistics
More informationPrognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes
Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes G. Cancello, P. Maisonneuve, N. Rotmensz, G. Viale, M. G. Mastropasqua, G.
More informationHer-2/neu expression and its correlation with ER status and various clinicopathological parameters
Original Research Article DOI: 10.5958/2394-6792.2016.00106.X Her-2/neu expression and its correlation with ER status and various clinicopathological parameters Kriti Chauhan 1,*, Monika Garg 2, Abhimanyu
More informationThe Oncotype DX Assay in the Contemporary Management of Invasive Early-stage Breast Cancer
The Oncotype DX Assay in the Contemporary Management of Invasive Early-stage Breast Cancer Cancer The Biology Century Understanding and treating the underlying tumor biology Cancer genetic studies demonstrate
More informationMorphological and Molecular Typing of breast Cancer
Morphological and Molecular Typing of breast Cancer Ian Ellis Molecular Medical Sciences, University of Nottingham Department of Histopathology, Nottingham University Hospitals NHS Trust Histological
More informationHormone receptor sensitivity in Breast Cancer patients in Pune city of Maharashtra State, India A retrospective study
International Journal of Advanced Biotechnology and Research(IJBR) ISSN 0976-2612, Online ISSN 2278 599X, Vol 6, Issue2, 2015, pp196-202 http://www.bipublication.com Research Article Hormone sensitivity
More informationRNA preparation from extracted paraffin cores:
Supplementary methods, Nielsen et al., A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor positive breast cancer.
More informationSupplementary Fig. 1: ATM is phosphorylated in HER2 breast cancer cell lines. (A) ATM is phosphorylated in SKBR3 cells depending on ATM and HER2
Supplementary Fig. 1: ATM is phosphorylated in HER2 breast cancer cell lines. (A) ATM is phosphorylated in SKBR3 cells depending on ATM and HER2 activity. Upper panel: Representative histograms for FACS
More informationOncotype DX testing in node-positive disease
Should gene array assays be routinely used in node positive disease? Yes Christy A. Russell, MD University of Southern California Oncotype DX testing in node-positive disease 1 Validity of the Oncotype
More informationTemporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008
Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,
More informationBreast Cancer Basics. Clinical Oncology for Public Health Professionals. Ben Ho Park, MD, PhD
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationTable of contents. Page 2 of 40
Page 1 of 40 Table of contents Introduction... 4 1. Background Information... 6 1a: Referral source for the New Zealand episodes... 6 1b. Invasive and DCIS episodes by referral source... 7 1d. Age of the
More informationMolecular Characterization of Breast Cancer: The Clinical Significance
Molecular Characterization of : The Clinical Significance Shahla Masood, M.D. Professor and Chair Department of Pathology and Laboratory Medicine University of Florida College of Medicine-Jacksonville
More informationDOCTORAL THESIS SUMMARY
UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA FACULTY OF MEDICINE DOCTORAL THESIS SUMMARY CLINICO-IMAGING STUDY OF INVASIVE DUCTAL BREAST CARCINOMAS CORRELATED TO HORMONAL RECEPTORS AND HER2/NEU ONCOPROTEIN
More informationEvaluation the Correlation between Ki67 and 5 Years Disease Free Survival of Breast Cancer Patients
BIOSCIENCES BIOTECHNOLOGY RESEARCH ASIA, December 2015. Vol. 12(3), 2221-2225 Evaluation the Correlation between Ki67 and 5 Years Disease Free Survival of Breast Cancer Patients S.M. Hosseini¹, H. Shahbaziyan
More informationAuthors: Thais Abreu de ALMEIDA 1, Institution:
Correlation of CYP2D6 s genotype and phenotype with clinicopathological characterization and impact on survival in Brazilian breast cancer population: a prospective study. Authors: Thais Abreu de ALMEIDA
More informationT he HER-2 gene encodes a 185 kda transmembrane
611 ORIGINAL ARTICLE Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer H J Huang, P Neven, M Drijkoningen, R Paridaens,
More informationCLINICOPATHOLOGIC FEATURES AND MOLECULAR SUBTYPES OF BREAST CANCER IN FEZ-MEKNES REGION (MOROCCO): A STUDY OF 390 PATIENTS
CLINICOPATHOLOGIC FEATURES AND MOLECULAR SUBTYPES OF BREAST CANCER IN FEZ-MEKNES REGION (MOROCCO): A STUDY OF 390 PATIENTS S. Chahbouni¹, A. Amarti 2, N. Hammas 3, L. Chbani 3, H. El fatemi 3 1 Department
More informationSesiones interhospitalarias de cáncer de mama. Revisión bibliográfica 4º trimestre 2015
Sesiones interhospitalarias de cáncer de mama Revisión bibliográfica 4º trimestre 2015 Selected papers Prospective Validation of a 21-Gene Expression Assay in Breast Cancer TAILORx. NEJM 2015 OS for fulvestrant
More informationRetrospective analysis to determine the use of tissue genomic analysis to predict the risk of recurrence in early stage invasive breast cancer.
Retrospective analysis to determine the use of tissue genomic analysis to predict the risk of recurrence in early stage invasive breast cancer. Goal of the study: 1.To assess whether patients at Truman
More information2016 CANCER PROGRAM REPORT. Bay Medical Sacred Heart Health System 615 North Bonita Avenue Panama City, FL
2016 CANCER PROGRAM REPORT Bay Medical Sacred Heart Health System 615 North Bonita Avenue Panama City, FL 32401 850.769.1511 www.baymedical.org 2016 Cancer Program Report Bay Medical Sacred Heart provides
More informationDuctal Carcinoma-in-Situ: New Concepts and Controversies
Ductal Carcinoma-in-Situ: New Concepts and Controversies James J. Stark, MD, FACP Medical Director, Cancer Program and Palliative Care Maryview Medical Center Professor of Medicine, EVMS Case Presentation
More informationHER2/neu Amplification in Breast Cancer Stratification by Tumor Type and Grade
Anatomic Pathology / HER2/NEU AMPLIFICATION IN BREAST CANCER HER2/neu Amplification in Breast Cancer Stratification by Tumor Type and Grade Elise R. Hoff, MD, Raymond R. Tubbs, DO, Jonathan L. Myles, MD,
More informationCirculating Tumor Cells in non- Metastatic Triple Negative Breast Cancer
Circulating Tumor Cells in non- Metastatic Triple Negative Breast Cancer Carolyn Hall, Ph.D. Department of Surgical Oncology The University of Texas MD Anderson Cancer Center Triple Negative Breast Cancer
More informationLocal Recurrence and Distant Metastases after Breast Conservation Treatment in Women with Triple Negative Breast Cancer Subtype
Local Recurrence and Distant Metastases after Breast Conservation Treatment in Women with Triple Negative Breast Cancer Subtype Amr Ghannam 1, Omnia Abd el-fattah 1 and Ayman El-Nemr 2 1 Clinical Oncology
More informationEstrogen Receptor, Progesterone Receptor, and Her-2/neu Oncogene Expression in Breast Cancers Among Bangladeshi Women
Journal of Bangladesh College of Physicians and Surgeons Vol. 28, No. 3, September 2010 Estrogen Receptor, Progesterone Receptor, and Her-2/neu Oncogene Expression in Breast Cancers Among Bangladeshi Women
More informationMale Breast Cancer in the Veterans Affairs Population
1471 Male Breast Cancer in the Veterans Affairs Population A Comparative Analysis Zeina A. Nahleh, MD 1,2 Roopa Srikantiah, MD 1,2 Malek Safa, MD 1,2 Abdul-Rahman Jazieh, MD 1 Albert Muhleman, MD 1,2 Rami
More informationNODE-POSITIVE BREAST cancers have a worse prognosis
Significance of Axillary Lymph Node Metastasis in Primary Breast Cancer By Ismail Jatoi, Susan G. Hilsenbeck, Gary M. Clark, and C. Kent Osborne Purpose: Axillary lymph node status is the single most important
More informationImmunohistochemical Expression of Hormone Receptors and The Histological Characteristics of Biochemically Hormone Receptor Negative Breast Cancers
Breast Cancer Vol. 14 No. 1 January 2007 Original Article Immunohistochemical Expression of Hormone Receptors and The Histological Characteristics of Biochemically Hormone Receptor Negative Breast Cancers
More informationResection Margins in Breast Conserving Surgery. Alberto Costa, MD Canton Ticino Breast Unit Lugano, Switzerland
Resection Margins in Breast Conserving Surgery Alberto Costa, MD Canton Ticino Breast Unit Lugano, Switzerland Breast Conserving Surgery 1 Probably one of the most important innovation in cancer surgery
More informationBreast pathology. 2nd Department of Pathology Semmelweis University
Breast pathology 2nd Department of Pathology Semmelweis University Breast pathology - Summary - Benign lesions - Acute mastitis - Plasma cell mastitis / duct ectasia - Fat necrosis - Fibrocystic change/
More information